AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02687945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient physiotherapy
Study NCT01446549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensive antigravity locomotor exercise
Description: High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
Study NCT02396108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin + ASLAN001
Description: Phase I~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~* PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~* PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks
Study NCT01446549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation implantation
Study NCT02461849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400mg qd daily
Study NCT02436915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
Study NCT02436915 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
Study NCT00149110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: 3 days with a normal night between
Study NCT02687945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided physiotherapy
Study NCT00149110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: Daily light therapy for 29 weeks
Study NCT00149110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diurnal rhythms
Description: Keeping the day-night cycle constant by use of educational measures
Study NCT00149110 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Moderate intensity daily exercise for 30 minutes at least
Study NCT00149110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 60 mg daily
Study NCT00149110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: 60 mg daily
Study NCT01877005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT01103830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riamet®
Description: 4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
Study NCT01103830 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo and finally Moxifloxacin
Description: 3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning.
Study NCT01103830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurartesim™
Description: 3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
Study NCT01103830 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo and finally Moxifloxacin
Description: 3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning.
Study NCT04653272 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will be evaluated identically to routine care with reference tests (Lysholm-Tegner, and Knee injury and Osteoarthritis Outcome Score (KOSS) and, IKDC (Evaluation of knee ligament injuries). This is filled in without any external help. The questionnaire includes the Lysholm-Tegner (young adult group), IKDC and KOOS scores (young and senior adult groups).
Study NCT03154515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin
Study NCT03154515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04367155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: hemostatics use
Study NCT01420224 — intervention group
Intervention type: OTHER
Intervention: Commercial airline flight
Description: Normal scheduled passenger flight
Study NCT02657694 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir+Ledipasvir
Description: DAA medication treatment
Study NCT02657694 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir+Daclatasvir
Description: DAA medication treatment
Study NCT02657694 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir+Velpatasvir
Description: DAA medication treatment
Study NCT06464731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVT
Description: Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines. This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on. The EVT regimen and relevant time points will be accurately recorded. The patient will receive the best medical treatment according to the local guidelines.
Study NCT03136224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocautery
Study NCT03136224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic Clamping
Study NCT03136224 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Surgical Circumcision
Study NCT04540029 — intervention group
Intervention type: OTHER
Intervention: Maternal stress
Description: Prenatal COVID-19-related stress retrospectively self-reported by mothers after delivery.
Study NCT01217814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT01217814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT01217814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT01217814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT01217814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT01948219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENTegral Artificial Larynx implant
Study NCT01217814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate (MTX)
Description: Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)
Study NCT01217814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate (MTX)
Description: Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)
Study NCT01217814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX)
Description: Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)
Study NCT01217814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic/folinic acid
Description: Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard.
Study NCT01217814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic/folinic acid
Description: Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard.
Study NCT01217814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic/folinic acid
Description: Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard.
Study NCT00864383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
Description: Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg > 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg > 55 kg - 75 kg 1500 mg > 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg > 55 kg - 75 kg 1200 mg > 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.
Study NCT00864383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
Description: Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg > 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg > 55 kg - 75 kg 1500 mg > 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg > 55 kg - 75 kg 1200 mg > 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.
Study NCT00913497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glulisine
Description: Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
Study NCT00913497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
Study NCT00879034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
Study NCT00879034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
Study NCT00879034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
Study NCT02672878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold
Study NCT02331589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRG (Korea Red ginseng)
Description: 3 weeks of KRG capsule (3,000 mg/day)
Study NCT02331589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for KRG)
Description: Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
Study NCT00293813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70 mg PO QW
Study NCT00293813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: denosumab 60 mg SC q 6 mos
Study NCT00293813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for alendronate and placebo for denosumab
Study NCT01581229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: noninvasive positive pressure ventilation
Description: Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
Study NCT01581229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen therapy
Description: In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
Study NCT02715830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty of distal arteries
Description: angioplasty of the arteries bellow-the-knee
Study NCT03866317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: All subjects will receive secukinumab 300 mg injections subcutaneously at week 0, 1, 2, 3, 4, then every 4 weeks until week 12.
Study NCT04120844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)-based patient empowerment program (PEP)
Description: Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change. Counselors use empathy and other techniques to create an atmosphere to help patients to explore the discrepancies between the goals and their current behavior. The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise.
Study NCT04120844 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Traditional lecture style health education
Description: The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI. We consciously avoided the inclusion of elements of self-reflection and motivation in these lectures.
Study NCT02841007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko neuromuscular electrostimulation device
Study NCT04317443 — intervention group
Intervention type: PROCEDURE
Intervention: Super-mini percutaneous nephrolithotomy (SMP)
Description: SMP will be performed under general anesthesia in prone/supine position. Renal puncture will be performed under ultrasound/fluoroscopy guidance based on the preference of the participating surgeon. Tracts will be dilated to 14 Fr. Stone fragmentation will be performed with holmium laser and fragments will be extracted with the active suction system. For the exit strategy, placement of a nephrostomy tube or JJ stent will be decided by the participating surgeon.
Study NCT04317443 — intervention group
Intervention type: PROCEDURE
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Description: ESWL will be performed under sedation/analgesia, shock wave lithotripsy parameters will be determined based on the device and the settings of local center. For patients requiring multiple sessions, maximum 3 (or more) sessions will be allowed. Ureteral stenting prior to ESWL will be performed based on the decision of the participating center.
Study NCT02295631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard tracheal tube
Description: ETI with standard tracheal tube and Macintosh laryngoscope
Study NCT02066246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirSeal
Description: 100 patients are treated with the AirSeal insufflation and trocar system
Study NCT02066246 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Olympus UHI-3
Description: 100 patients are treated with a conventional insufflation and trocar system
Study NCT01022632 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
Study NCT01022632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
Study NCT01022632 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin and Fluoxetine
Description: Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
Study NCT04391127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine: 400 mg PO every 12 hours for one day. Subsequently 200 mg every 12 hours per 4 more days.
Study NCT04391127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 12 mg PO every 24 hours for one day (in case of weight less than 80 kg) or 18 mg PO every 24 hours for one day (in case of weight over 80 kg) Subsequently this group will take two tablets of placebo 12 hrs after ivermectin ingestion and then one tablet of placebo each 12 hrs per 4 more days.
Study NCT04391127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.
Study NCT03802669 — intervention group
Intervention type: OTHER
Intervention: oral mutans streptococcus
Description: quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern
Study NCT01889004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Escalating concentrations until loss of responsiveness
Study NCT01889004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Escalating concentrations until loss of responsiveness
Study NCT03170401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: enteral protein supplementation
Study NCT03170401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard enteral nutrition
Description: Standard enteral nutrition.
Study NCT02034292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APD791
Study NCT02034292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04480918 — intervention group
Intervention type: DEVICE
Intervention: Electroconvulsive Therapy (ECT)
Description: ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode
Study NCT04480918 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS for the treatment of treatment-resistant depression in an active major depressive episode
Study NCT04480918 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode
Study NCT04480918 — intervention group
Intervention type: DRUG
Intervention: Esketamine
Description: Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode
Study NCT04480918 — intervention group
Intervention type: DEVICE
Intervention: Deep Transcranial Magnetic Stimulation (dTMS)
Description: TMS for the treatment of OCD
Study NCT00499577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV pp65 peptide
Description: Given intramuscularly
Study NCT00499577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT I540/R572Y/D988Y multipeptide vaccine
Description: Given subcutaneously
Study NCT00499577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal polyvalent vaccine
Description: Given intramuscularly
Study NCT00499577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: survivin Sur1M2 peptide vaccine
Description: Given subcutaneously
Study NCT00894660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine (Test)
Description: Oral tablet, single dose, 1 X 300 MG
Study NCT00894660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine (Comparator)
Description: Oral tablet, single dose, 2 X 150 MG
Study NCT00820690 — intervention group
Intervention type: DRUG
Intervention: doxorubicin
Description: 4 cycles AC: doxorubicin 60mg/m2
Study NCT00580593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP® S/T System
Description: The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.